The NHS North East Treatment Advisory Group (NETAG) has issued a recommendation and associated appraisal report on pegvisomant (Somavert) for acromegaly. The Group did not recommend its use as it considered that pegvisomant is unlikely to meet conventional cost effectiveness criteria. However it accepted that individual patients in exceptional circumstances may be suitable for treatment, and such cases must be referred via local individual funding request mechanisms.